10.05.20

Oculis Announces Presentation of Positive Results From Phase 2 Trial of OCS-01 in Patients With Diabetic Macular Edema (DME)

Source: Oculis

09.01.20

Oculis Establishes Presence in US and Appoints Sylvia Cheung as Chief Financial Officer

Source: Oculis

07.27.20

Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications

Source: Oculis

05.18.20

Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery

Source: Oculis

05.07.20

Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery

Source: Oculis

02.10.20

Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)

Source: Oculis

10.07.19

Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Source: Oculis

09.17.19

Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board

Source: Oculis

01.04.19

Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartis

Source: Oculis

01.04.19

Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseases

Source: Oculis

View more stories